Active — Not RecruitingNot Applicable

Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France

France302 participantsStarted 2023-12-21

Plain-language summary

SEPROS is a non-interventional study, based on primary data collection of MS adult patients who initiated ofatumumab as per neurologist practice and regardless of the study protocol.

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or female, 18 years of age or older
✓. Patient with confirmed MS diagnosis
✓. Patient initiating treatment with ofatumumab for the first time
✓. Patient for which the decision to initiate treatment with ofatumumab was made by the doctor (investigator) in accordance with his/her usual practices independently of the study
✓. Patient not opposed to participation in this study
✓. Patient willing and able to complete patient questionnaires

What they're measuring

Quality of life - MUSIQoL questionnaire

Timeframe: 12 months

Trial details

NCT IDNCT06157086

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-07-31

View on ClinicalTrials.gov More Multiple Sclerosis (MS) trials